Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CAMKK1 | Q8N5S9 | 4/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705927 | 0.98 | KMO (0.46) | ACMSDKMOPTGDR2ALDH1A1ALOX15 | |
| Phthalic Acid SCHEMBL11409627 | 0.97 | ALDH1A1 (0.47) | ACMSDKMOPTGDR2ALDH1A1ALOX15 | |
| SCHEMBL3113022 | 0.96 | ACMSD (0.40) | ACMSDKMOPTGDR2ALDH1A1ALOX15 | |
| SCHEMBL29804902 | 0.96 | ACMSD (0.40) | ACMSDKMOPTGDR2ALDH1A1ALOX15 | |
| Phthalic Acid SCHEMBL11407238 | 0.95 | PTGDR2 (0.47) | ACMSDKMOPTGDR2ALDH1A1ALOX15 | |
| SCHEMBL17323529 | 0.89 | KMO (0.49) | ACMSDKMOPTGDR2CAMKK2CAMKK1 | |
| SCHEMBL17323537 | 0.87 | KMO (0.51) | ACMSDKMOPTGDR2ALDH1A1 | |
| SCHEMBL17323545 | 0.87 | KMO (0.51) | ACMSDKMOPTGDR2ALDH1A1 | |
| SCHEMBL17323530 | 0.87 | KMO (0.51) | ACMSDKMOPTGDR2ALDH1A1 | |
| SCHEMBL973373 | 0.87 | KDM4E (0.43) | ACMSDKMOPTGDR2CAMKK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041679-B | Polycarbonate biodegradable elastomer and preparation method thereof | 山东联欣环保科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11352338-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3880669-A1 | SUBSTITUTED ISOINDOLINONES | Biotheryx, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-113423701-A | Substituted isoindolinones | 拜欧斯瑞克斯公司 | 2021-09-21 | — | — | CN | disclosed |
| US-10844039-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| WO-2020102195-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-4229431-A | IN SITU POLYMERIZATION | LEE PHARMACEUTICALS (US) | 1980-10-21 | — | — | US | disclosed |
| US-4104333-A | COMPOSITIONS CONTAINING CROSSLINKING MONOMERS, MONOACRYLATES, INITIATORS AND ACCELERATORS | LEE PHARMACEUTICALS (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | ACMSD 4579/4885KMO 3303/4885PTGDR2 1529/4885 |
| US-10844039-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | ACMSD 4579/4885KMO 3303/4885PTGDR2 1529/4885 |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | ACMSD 4579/4885KMO 3303/4885PTGDR2 1529/4885 |
| US-11352338-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | ACMSD 4579/4885KMO 3303/4885PTGDR2 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.